These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 9432125)
21. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Thompson PM; Maris JM; Hogarty MD; Seeger RC; Reynolds CP; Brodeur GM; White PS Cancer Res; 2001 Jan; 61(2):679-86. PubMed ID: 11212268 [TBL] [Abstract][Full Text] [Related]
22. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Walker GJ; Flores JF; Glendening JM; Lin AH; Markl ID; Fountain JW Genes Chromosomes Cancer; 1998 Jun; 22(2):157-63. PubMed ID: 9598804 [TBL] [Abstract][Full Text] [Related]
23. Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Weber RG; Hoischen A; Ehrler M; Zipper P; Kaulich K; Blaschke B; Becker AJ; Weber-Mangal S; Jauch A; Radlwimmer B; Schramm J; Wiestler OD; Lichter P; Reifenberger G Oncogene; 2007 Feb; 26(7):1088-97. PubMed ID: 16909113 [TBL] [Abstract][Full Text] [Related]
24. Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma. Gebauer S; Yu AL; Omura-Minamisawa M; Batova A; Diccianni MB Genes Chromosomes Cancer; 2004 Dec; 41(4):297-308. PubMed ID: 15390183 [TBL] [Abstract][Full Text] [Related]
25. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas. Kirsch M; Mörz M; Pinzer T; Schackert HK; Schackert G Genes Chromosomes Cancer; 2009 Feb; 48(2):143-54. PubMed ID: 18973139 [TBL] [Abstract][Full Text] [Related]
26. Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. Schmidt EE; Ichimura K; Messerle KR; Goike HM; Collins VP Br J Cancer; 1997; 75(1):2-8. PubMed ID: 9000591 [TBL] [Abstract][Full Text] [Related]
27. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma. Takita J; Hayashi Y; Kohno T; Yamaguchi N; Hanada R; Yamamoto K; Yokota J Cancer Res; 1997 Mar; 57(5):907-12. PubMed ID: 9041193 [TBL] [Abstract][Full Text] [Related]
28. Identification and mapping of swine cyclin-dependent kinase inhibitor CDKN2A and CDKN2B exon 2 sequences. Le Chalony C; Hayes H; Frelat G; Geffrotin C Cytogenet Cell Genet; 2000; 88(3-4):240-3. PubMed ID: 10828598 [TBL] [Abstract][Full Text] [Related]
29. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors. Heidenreich A; Gaddipati JP; Moul JW; Srivastava S J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401 [TBL] [Abstract][Full Text] [Related]
30. Expression of Chr9p21 genes CDKN2B (p15(INK4b)), CDKN2A (p16(INK4a), p14(ARF)) and MTAP in human atherosclerotic plaque. Holdt LM; Sass K; Gäbel G; Bergert H; Thiery J; Teupser D Atherosclerosis; 2011 Feb; 214(2):264-70. PubMed ID: 20637465 [TBL] [Abstract][Full Text] [Related]
31. The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes. Stadler WM; Olopade OI Urol Res; 1996; 24(4):239-44. PubMed ID: 8873383 [TBL] [Abstract][Full Text] [Related]
32. Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: evidence for two deleted regions. Marshall B; Isidro G; Martins AG; Boavida MG Cancer Genet Cytogenet; 1997 Jul; 96(2):134-9. PubMed ID: 9216721 [TBL] [Abstract][Full Text] [Related]
33. Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas. Bisogna M; Calvano JE; Ho GH; Orlow I; Cordón-Cardó C; Borgen PI; Van Zee KJ Cancer Genet Cytogenet; 2001 Mar; 125(2):131-8. PubMed ID: 11369056 [TBL] [Abstract][Full Text] [Related]
34. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Bertin R; Acquaviva C; Mirebeau D; Guidal-Giroux C; Vilmer E; Cavé H Genes Chromosomes Cancer; 2003 May; 37(1):44-57. PubMed ID: 12661005 [TBL] [Abstract][Full Text] [Related]
35. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622 [TBL] [Abstract][Full Text] [Related]
36. A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. Schmid M; Sen M; Rosenbach MD; Carrera CJ; Friedman H; Carson DA Oncogene; 2000 Nov; 19(50):5747-54. PubMed ID: 11126361 [TBL] [Abstract][Full Text] [Related]
38. Mutations, methylation and expression of CDKN2a/p16 gene in colorectal cancer and normal colonic mucosa. Trzeciak L; Hennig E; Kolodziejski J; Nowacki M; Ostrowski J Cancer Lett; 2001 Feb; 163(1):17-23. PubMed ID: 11163104 [TBL] [Abstract][Full Text] [Related]
39. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Iolascon A; Faienza MF; Coppola B; Rosolen A; Basso G; Della Ragione F; Schettini F Genes Chromosomes Cancer; 1996 Apr; 15(4):217-22. PubMed ID: 8703847 [TBL] [Abstract][Full Text] [Related]
40. Association of CDKN2A/p16INK4A with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. Loughran O; Malliri A; Owens D; Gallimore PH; Stanley MA; Ozanne B; Frame MC; Parkinson EK Oncogene; 1996 Aug; 13(3):561-8. PubMed ID: 8760298 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]